Biotech Values

[DewDiligence]

EGRX +31% since your post (#msg-118181890, bottom)—nicely done.

As you know, I think EGRX is just warming up for what I hope will be a big December: two PDUFA dates and one major data release.

Moreover, an Angiomax partnership with MDCO could be back on the table if the CAFC en banc rehearing reverses the original appellate ruling (#msg-118484166).

Further, a buyout by TEVA is an ever-present possibility. On the other hand, EGRX is more than capable of staying independent and turning into a cash-generation machine as Bendec and EGRX’s wholly owned products come to market.